Charles Schwab Investment Management Inc Taysha Gene Therapies, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 474,257 shares of TSHA stock, worth $853,662. This represents 0.0% of its overall portfolio holdings.
Number of Shares
474,257
Previous 462,867
2.46%
Holding current value
$853,662
Previous $930,000
11.83%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding TSHA
# of Institutions
129Shares Held
150MCall Options Held
48KPut Options Held
7.8K-
Avoro Capital Advisors LLC New York, NY20MShares$36 Million0.5% of portfolio
-
Morgan Stanley New York, NY17.6MShares$31.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$21.1 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$19.6 Million0.3% of portfolio
-
Octagon Capital Advisors LP New York, NY10.5MShares$18.8 Million4.03% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $87M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...